GlassScriptPhysician profile
Daisy Lara
NPI 1083081772
$6,884.45
in general payments reported to CMS, 2019-2025
17 companies · $2,386 in 2025
The $2,386 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $58.67 · 2022: $887 · 2023: $1,980 · 2024: $1,572 · 2025: $2,386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,892 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,891.85 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,522.37 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,062.19 | 2023-2025 | Ingrezza |
| Alkermes, INC. | $921.04 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $789.97 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $565.51 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $450.75 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $417.84 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $264.83 | 2022-2025 | Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $197.34 | 2023 | Spravato, Invega Sustenna, Invega Trinza |
| Supernus Pharmaceuticals, INC. | $160.31 | 2025 | Qelbree |
| Vanda Pharmaceuticals INC. | $145.73 | 2022-2025 | Fanapt |
| Corium, LLC | $137.97 | 2022-2024 | Azstarys |
| Tempus Ai, INC | $96.64 | 2024 | |
| Lundbeck LLC | $73.02 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $40.05 | 2025 | Trintellix |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $21.41 | 2024 | Adzenys Xr-Odt |
| Lilly USA, LLC | $17.48 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daisy Lara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.